Novartis invests in Selexys with exclusive option to acquire the company; option exercised
Executive Summary
Novartis Pharmaceuticals Corp. has been granted an exclusive option to acquire closely held Selexys Pharmaceuticals Corp. (therapeutics for inflammatory and thrombotic diseases) after it completes a Phase II study of the anti-P-selectin antibody SelG1, which recently finished Phase I for vaso-occlusive crisis, a major complication in patients with sickle cell disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice